On­coIm­mune rais­es $15M for PhII GvHD study; FDA wraps biosim­i­lar nam­ing guid­ance

• Rockville, MD-based On­coIm­mune has raised a $15 mil­lion Se­ries A round. 3E Bioven­tures Cap­i­tal led the round, which is pri­mar­i­ly fo­cused on a ther­a­py that tar­gets the CD24-Siglec path­way. The biotech be­lieves they can fol­low this tar­get to a new ap­proach in reg­u­lat­ing an in­flam­ma­to­ry re­sponse to tis­sue in­juries, play­ing a role in au­toim­mune dis­eases, can­cer and graft-ver­sus-host dis­ease. The lead drug, CD24Fc, is go­ing in­to Phase II for GvHD.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.